← Back to headlines
Ocular Gains Following EyePoint's Wet AMD Phase 3 Miss
Ocular has seen gains in its stock following EyePoint's unsuccessful Phase 3 trial for wet Age-related Macular Degeneration (AMD).
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.